DAA (direct acting antiviral) – new hepatitis C drugs that work directly against the hepatitis C virus (HCV).
Since 2014, the following DAAs and fixed dose combinations have been approved – and more are in development. Links are to the EMA website for information on each DAA.
- daclatasvir 30, 60, and 90 mg (Daklinza)
- dasabuvir 250 mg (Exviera)
- sofosbuvir / ledispavir 400 mg / 90 mg (Harvoni)
- simepravir 150 mg (Olysio)
- sofosbuvir 400 mg (Sovaldi)
- ombitasvir / paritaprevir / ritonavir 2.5 mg / 75 mg / 50 mg (Viekirax)
- elbasvir / grazoprevir 50 mg /100 mg (Zepatier)
Previously, HCV was treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV).
Even though HCV guidelines now only recommend oral DAA treatment, the high price of these medicines means that in many countries they are only available to people who have advanced liver damage.